2021 APASL共识指南:药物性肝损伤

2021-02-27 亚太肝脏研究学会 Hepatol Int . 2021 Feb 27.

特异性药物引起的肝损伤模仿急性和慢性肝病。由于缺乏病理诊断性的血清学标志物,因此对其认识不足,没有得到充分的认可。其后果可从无症状到自限性疾病到严重肝损伤导致急性肝衰竭。其发病率在亚洲可能比世界其他地

中文标题:

2021 APASL共识指南:药物性肝损伤

英文标题:

Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines

发布机构:

亚太肝脏研究学会

发布日期:

2021-02-27

简要介绍:

特异性药物引起的肝损伤模仿急性和慢性肝病。由于缺乏病理诊断性的血清学标志物,因此对其认识不足,没有得到充分的认可。其后果可从无症状到自限性疾病到严重肝损伤导致急性肝衰竭。其发病率在亚洲可能比世界其他地区更常见,主要原因是亚洲国家治疗结核病所产生的肝毒性以及传统药物和辅助药物的普遍使用。这份APASL关于DILI的共识指南简明扼要地阐述了各方面的情况,包括目前关于DILI的循证资料,并特别强调了亚洲地区因抗结核药物和传统及补充药物使用而导致的DILI。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2021 APASL共识指南:药物性肝损伤.pdf)] GetToolGuiderByIdResponse(projectId=1, id=c04d31c0020e15b5, title=2021 APASL共识指南:药物性肝损伤, enTitle=Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines, guiderFrom=Hepatol Int . 2021 Feb 27., authorId=0, author=, summary=特异性药物引起的肝损伤模仿急性和慢性肝病。由于缺乏病理诊断性的血清学标志物,因此对其认识不足,没有得到充分的认可。其后果可从无症状到自限性疾病到严重肝损伤导致急性肝衰竭。其发病率在亚洲可能比世界其他地, cover=https://img.medsci.cn/2021315/1615739124840_2020535.jpg, journalId=0, articlesId=null, associationId=97, associationName=亚太肝脏研究学会, associationIntro=亚太肝病学会1978年在新加坡成立,其成员国北至中国,南到澳大利亚,东部包括了太平洋的各个岛国,西部包括到伊朗。亚太肝病学会也是国际肝病学会的成员之一,《Hepatology International》是亚太肝病学会的官方杂志。, copyright=0, guiderPublishedTime=Sat Feb 27 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="bp3-card bp3-elevation-0 result-block" style="color: #182026;"> <div class="common-result"> <div class="general-result"> <p>特异性药物引起的肝损伤模仿急性和慢性肝病。由于缺乏病理诊断性的血清学标志物,因此对其认识不足,没有得到充分的认可。其后果可从无症状到自限性疾病到严重肝损伤导致急性肝衰竭。其发病率在亚洲可能比世界其他地区更常见,主要原因是亚洲国家治疗结核病所产生的肝毒性以及传统药物和辅助药物的普遍使用。这份APASL关于DILI的共识指南简明扼要地阐述了各方面的情况,包括目前关于DILI的循证资料,并特别强调了亚洲地区因抗结核药物和传统及补充药物使用而导致的DILI。</p> </div> </div> </div>, tagList=[TagDto(tagId=605, tagName=药物性肝损伤)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=22, categoryName=肝病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=605, guiderKeyword=药物性肝损伤, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=37428, appHits=667, showAppHits=0, pcHits=1961, showPcHits=36761, likes=9, shares=41, comments=41, approvalStatus=1, publishedTime=Mon Mar 15 00:36:48 CST 2021, publishedTimeString=2021-02-27, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Mon Mar 15 00:25:33 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 18:13:59 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 APASL共识指南:药物性肝损伤.pdf)])
2021 APASL共识指南:药物性肝损伤.pdf
下载请点击:
评论区 (35)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2153863, encodeId=997c2153863c2, content=学习中, beContent=null, objectType=guider, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a086217732, createdName=58432_7056, createdTime=Mon Aug 21 14:29:33 CST 2023, time=2023-08-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2094129, encodeId=87be2094129eb, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd18380585, createdName=ms1000000210992015, createdTime=Sun Oct 16 23:38:12 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071837, encodeId=5d4010e1837bc, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33125549638, createdName=ms2000002041300407, createdTime=Fri Nov 19 19:05:33 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069422, encodeId=f69810694226a, content=厉害 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac6e5204779, createdName=14748599m53暂无昵称, createdTime=Fri Nov 12 00:23:42 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058635, encodeId=3ffa1058635cb, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=887b5610574, createdName=ms1000002121020113, createdTime=Fri Oct 08 15:15:15 CST 2021, time=2021-10-08, status=1, ipAttribution=)]
    2023-08-21 58432_7056 来自山东省

    学习中

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2153863, encodeId=997c2153863c2, content=学习中, beContent=null, objectType=guider, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a086217732, createdName=58432_7056, createdTime=Mon Aug 21 14:29:33 CST 2023, time=2023-08-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2094129, encodeId=87be2094129eb, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd18380585, createdName=ms1000000210992015, createdTime=Sun Oct 16 23:38:12 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071837, encodeId=5d4010e1837bc, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33125549638, createdName=ms2000002041300407, createdTime=Fri Nov 19 19:05:33 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069422, encodeId=f69810694226a, content=厉害 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac6e5204779, createdName=14748599m53暂无昵称, createdTime=Fri Nov 12 00:23:42 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058635, encodeId=3ffa1058635cb, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=887b5610574, createdName=ms1000002121020113, createdTime=Fri Oct 08 15:15:15 CST 2021, time=2021-10-08, status=1, ipAttribution=)]
    2022-10-16 ms1000000210992015

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2153863, encodeId=997c2153863c2, content=学习中, beContent=null, objectType=guider, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a086217732, createdName=58432_7056, createdTime=Mon Aug 21 14:29:33 CST 2023, time=2023-08-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2094129, encodeId=87be2094129eb, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd18380585, createdName=ms1000000210992015, createdTime=Sun Oct 16 23:38:12 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071837, encodeId=5d4010e1837bc, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33125549638, createdName=ms2000002041300407, createdTime=Fri Nov 19 19:05:33 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069422, encodeId=f69810694226a, content=厉害 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac6e5204779, createdName=14748599m53暂无昵称, createdTime=Fri Nov 12 00:23:42 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058635, encodeId=3ffa1058635cb, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=887b5610574, createdName=ms1000002121020113, createdTime=Fri Oct 08 15:15:15 CST 2021, time=2021-10-08, status=1, ipAttribution=)]
    2021-11-19 ms2000002041300407

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2153863, encodeId=997c2153863c2, content=学习中, beContent=null, objectType=guider, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a086217732, createdName=58432_7056, createdTime=Mon Aug 21 14:29:33 CST 2023, time=2023-08-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2094129, encodeId=87be2094129eb, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd18380585, createdName=ms1000000210992015, createdTime=Sun Oct 16 23:38:12 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071837, encodeId=5d4010e1837bc, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33125549638, createdName=ms2000002041300407, createdTime=Fri Nov 19 19:05:33 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069422, encodeId=f69810694226a, content=厉害 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac6e5204779, createdName=14748599m53暂无昵称, createdTime=Fri Nov 12 00:23:42 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058635, encodeId=3ffa1058635cb, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=887b5610574, createdName=ms1000002121020113, createdTime=Fri Oct 08 15:15:15 CST 2021, time=2021-10-08, status=1, ipAttribution=)]
    2021-11-12 14748599m53暂无昵称

    厉害

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2153863, encodeId=997c2153863c2, content=学习中, beContent=null, objectType=guider, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a086217732, createdName=58432_7056, createdTime=Mon Aug 21 14:29:33 CST 2023, time=2023-08-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2094129, encodeId=87be2094129eb, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd18380585, createdName=ms1000000210992015, createdTime=Sun Oct 16 23:38:12 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071837, encodeId=5d4010e1837bc, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33125549638, createdName=ms2000002041300407, createdTime=Fri Nov 19 19:05:33 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069422, encodeId=f69810694226a, content=厉害 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac6e5204779, createdName=14748599m53暂无昵称, createdTime=Fri Nov 12 00:23:42 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058635, encodeId=3ffa1058635cb, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=887b5610574, createdName=ms1000002121020113, createdTime=Fri Oct 08 15:15:15 CST 2021, time=2021-10-08, status=1, ipAttribution=)]
    2021-10-08 ms1000002121020113

    学习

    0

拓展阅读

2014 ACG 药物性肝损伤诊断和管理临床指南

美国胃肠病学院(ACG,American College of Gastroenterology) · 2014-06-17

药物性肝损伤诊治指南2015版

中华医学会肝病学分会(Chinese Society of Hepatology, CMA) · 2016-06-02

2016 血液病患者药物性肝损伤的预防和规范化治疗专家共识(2016年版)

中国临床肿瘤学会(CSCO,Chinese Society of Clinical Oncology) · 2016-06-30

2019 EASL临床实践指南:药物性肝损伤

欧洲肝脏研究学会(EASL,European Association for the Study of the Liver) · 2019-03-26

药物性肝损伤基层诊疗指南(2019年)

中华医学会(CMA,Chinese Medical Association) · 2020-10-20